Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers - PubMed (original) (raw)
. 2010 Jul 15;16(14):3548-61.
doi: 10.1158/1078-0432.CCR-09-2797. Epub 2010 Jul 6.
Dawn Baker, Neil H James, Kirsty Ratcliffe, Martin Jenkins, Susan E Ashton, Graham Sproat, Ruth Swann, Neil Gray, Anderson Ryan, Juliane M Jürgensmeier, Chris Womack
Affiliations
- PMID: 20606037
- DOI: 10.1158/1078-0432.CCR-09-2797
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers
Neil R Smith et al. Clin Cancer Res. 2010.
Abstract
Purpose: Vascular endothelial growth factor (VEGF) signaling is key to tumor angiogenesis and is an important target in the development of anticancer drugs. However, VEGF receptor (VEGFR) expression in human cancers, particularly the relative expression of VEGFR-2 and VEGFR-3 in tumor vasculature versus tumor cells, is poorly defined.
Experimental design: VEGFR-2- and VEGFR-3-specific antibodies were identified and used in the immunohistochemical analysis of human primary cancers and normal tissue. The relative vascular localization of both receptors in colorectal and breast cancers was determined by coimmunofluorescence with vascular markers.
Results: VEGFR-2 and VEGFR-3 were expressed on vascular endothelium but not on malignant cells in 13 common human solid tumor types (n > 400, bladder, breast, colorectal, head and neck, liver, lung, skin, ovarian, pancreatic, prostate, renal, stomach, and thyroid). The signal intensity of both receptors was significantly greater in vessels associated with malignant colorectal, lung, and breast than adjacent nontumor tissue. In colorectal cancers, VEGFR-2 was expressed on both intratumoral blood and lymphatic vessels, whereas VEGFR-3 was found predominantly on lymphatic vessels. In breast cancers, both receptors were localized to and upregulated on blood vessels.
Conclusions: VEGFR-2 and VEGFR-3 are primarily localized to, and significantly upregulated on, tumor vasculature (blood and/or lymphatic) supporting the majority of solid cancers. The primary clinical mechanism of action of VEGF signaling inhibitors is likely to be through the targeting of tumor vessels rather than tumor cells. The upregulation of VEGFR-3 on tumor blood vessels indicates a potential additional antiangiogenic effect for dual VEGFR-2/VEGFR-3-targeted therapy.
Copyright 2010 AACR.
Similar articles
- Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma.
Lalla RV, Boisoneau DS, Spiro JD, Kreutzer DL. Lalla RV, et al. Arch Otolaryngol Head Neck Surg. 2003 Aug;129(8):882-8. doi: 10.1001/archotol.129.8.882. Arch Otolaryngol Head Neck Surg. 2003. PMID: 12925349 - Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM. Bruns CJ, et al. Cancer. 2000 Aug 1;89(3):488-99. Cancer. 2000. PMID: 10931447 - Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG. Beebe JS, et al. Cancer Res. 2003 Nov 1;63(21):7301-9. Cancer Res. 2003. PMID: 14612527 - Vascular galectins: regulators of tumor progression and targets for cancer therapy.
Thijssen VL, Rabinovich GA, Griffioen AW. Thijssen VL, et al. Cytokine Growth Factor Rev. 2013 Dec;24(6):547-58. doi: 10.1016/j.cytogfr.2013.07.003. Epub 2013 Aug 12. Cytokine Growth Factor Rev. 2013. PMID: 23942184 Review. - New developments in in vivo models of neoplasia.
Fidler IJ. Fidler IJ. Cancer Metastasis Rev. 1991 Oct;10(3):191-2. doi: 10.1007/BF00050790. Cancer Metastasis Rev. 1991. PMID: 1764763 Review. No abstract available.
Cited by
- Trial watch: DNA vaccines for cancer therapy.
Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Senovilla L, et al. Oncoimmunology. 2013 Apr 1;2(4):e23803. doi: 10.4161/onci.23803. Oncoimmunology. 2013. PMID: 23734328 Free PMC article. - Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.
Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Alfaleh MA, et al. Front Immunol. 2020 Aug 28;11:1986. doi: 10.3389/fimmu.2020.01986. eCollection 2020. Front Immunol. 2020. PMID: 32983137 Free PMC article. Review. - Synthesis and in vitro evaluation of 18F-FEPAQ: a potential PET ligand for VEGFR2.
Prabhakaran J, Arango V, Majo VJ, Simpson NR, Kassir SA, Underwood MD, Polavarapu H, Bruce JN, Canoll P, Mann JJ, Kumar JS. Prabhakaran J, et al. Bioorg Med Chem Lett. 2012 Aug 1;22(15):5104-7. doi: 10.1016/j.bmcl.2012.05.099. Epub 2012 Jun 7. Bioorg Med Chem Lett. 2012. PMID: 22749281 Free PMC article. - A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN, Cance WG. Kurenova E, et al. Cell Cycle. 2014;13(16):2542-53. doi: 10.4161/15384101.2015.941760. Cell Cycle. 2014. PMID: 25486195 Free PMC article. - The Evolution of Safe and Effective Coaguligands for Vascular Targeting and Precision Thrombosis of Solid Tumors and Vascular Malformations.
Faqihi F, Stoodley MA, McRobb LS. Faqihi F, et al. Biomedicines. 2021 Jul 4;9(7):776. doi: 10.3390/biomedicines9070776. Biomedicines. 2021. PMID: 34356840 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous